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Abstract
Background: Isolated limb perfusion with TNF-a and melphalan is used with remarkable efficiency to treat unresectable
limb sarcomas. Here we tested the ability of TNF-a to directly induce apoptosis of sarcoma cells. In addition, we investigated
the impact of p53 in the regulation of such effect.
Methodology/Principal Findings: We first analysed the ability of TNF-a to induce apoptosis in freshly isolated tumour cells.
For this purpose, sarcoma tumours (n=8) treated ex vivo with TNF-a were processed for TUNEL staining. It revealed
substantial endothelial cell apoptosis and levels of tumour cell apoptosis that varied from low to high. In order to
investigate the role of p53 in TNF-a-induced cell death, human sarcoma cell lines (n=9) with different TP53 and MDM2
status were studied for their sensitivity to TNF-a. TP53
Wt cell lines were sensitive to TNF-a unless MDM2 was over-expressed.
However, TP53
Mut and TP53
Null cell lines were resistant. TP53 suppression in TP53
Wt cell lines abrogated TNF-a sensitivity and
TP53 overexpression in TP53
Null cell lines restored it. The use of small molecules that restore p53 activity, such as CP-31398
or Nutlin-3a, in association with TNF-a, potentiated the cell death of respectively TP53
Mut and TP53
Wt/MDM2
Ampl.I n
particular, CP-31398 was able to induce p53 as well as some of its apoptotic target genes in TP53
Mut cells. In TP53
Wt/
MDM2
Ampl cells, Nutlin-3a effects were associated with a decrease of TNF-a-induced NF-kB-DNA binding and correlated with
a differential regulation of pro- and anti-apoptotic genes such as TP53BP2, GADD45, TGF-b1 and FAIM.
Conclusion/Significance: More effective therapeutic approaches are critically needed for the treatment of unresectable
limb sarcomas. Our results show that restoring p53 activity in sarcoma cells correlated with increased sensitivity to TNF-a,
suggesting that this strategy may be an important determinant of TNF-a-based sarcomas treatment.
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Introduction
Sarcomas are rare, poorly understood cancers, refractory to
standard therapies [1,2]. In this context, isolated limb perfusion
(ILP), a highly specialized surgical technique that allows higher
drug concentrations to be delivered loco-regionally, thus limiting
treatment toxicity, can be used to treat unresectable soft tissue
sarcomas (STS) of extremities avoiding limb amputation. During
ILP, the treatment agents are circulated through the vasculature of
the extremity using an extracorporeal pump oxygenator bypass
circuit [3]. The combination of TNF-a and melphalan through
ILP has been widely used to treat STS with impressive clinical
responses [4,5].
While the effect of melphalan, as a DNA-damaging alkylating
agent, is clearly established, the effect of TNF-a remains
controversial even though a TNF-a selective anti-vascular
mechanism has been established [6]. Indeed, radiological studies
demonstrated the selective disappearance of tumour hypervascu-
larized areas after treatment with TNF-a [7]. Moreover, the
tumour vascular disruption correlates in vivo with the induction of
endothelial cell apoptosis [8] and in vitro with the specific
suppression of aVb3-mediated endothelial cell adhesion [9]. More
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38808recently, it has been demonstrated that VE-cadherin is a target of
TNF-a, leading to the alteration of vascular integrity and tumour
viability [10]. It has also been demonstrated that TNF-a increases
intratumoural vessel permeability and reduces interstitial pressure,
facilitating drug penetration in tumours [11]. These data suggest
that the potent antitumour activity of ILP with TNF-a and
melphalan is due to a dual targeting effect: first, TNF-a increases
the permeability of tumour vessels and then melphalan reaches the
tumour cells and induces cell death. However, a more complex
process, in which TNF-a directly affects tumour cells, has also
been postulated [12,13].
TNF-a has been demonstrated to be either anti-proliferative,
growth enhancing, or ineffective on transformed cell lines [14] as
well as in early clinical trials when administered systemically [15].
In addition to this wide variation in sensitivity of tumour cells, the
therapeutic value of TNF-a in the treatment of cancer has been
limited by toxicity at high doses [3]. Even if the locoregional
administration of TNF-a by ILP is able to partially attenuate its
systemic toxic side effects, the resistance of some tumour cells to
the cytotoxic action of TNF-a remains a barrier to its effective
application [16]. Therefore, understanding the molecular and
biochemical mechanisms of tumour cell resistance to the cytotoxic
action of TNF-a may ultimately provide new approaches to
enhance the therapeutic effectiveness of TNF-a against human
malignancies [17].
In this regard, the dependence of TNF-a-induced cell death on
TP53 status was reported in vitro [18,19] and in vivo in sarcoma
patients treated with TNF-a and melphalan [20]. It should be
noted that TP53 is mutated in more than 20% or non functional in
up to 60% of STS (IARC TP53 mutation database, R15 release,
Nov. 2010) [21]. Moreover, a recent study on 143 various STS
showed that the p53/p14 pathway was altered in all analysed
tumours [22]. Furthermore, it is well established that p53 may
retain its wild-type configuration while being functionally
repressed through epistatic mechanisms, most frequently via
over-expression of MDM2 protein and MDM2 gene amplification
(MDM2
Ampl). Importantly, TP53 mutations or inactivations were
found to correlate with a poorer outcome in sarcoma patients [23].
It has been reported that pharmacological and/or genetic
restoration of the wild-type p53 pathway induce tumour cell
death in vitro and inhibit tumour growth in animal models [24].
The recent emergence of small molecules restoring the wild-type
conformation of mutant p53 protein, as well as blocking the
MDM2-p53 interaction, is likely to become a promising anti-
tumour strategy. In this context, the conformational changes
observed in the case of missense mutation of p53 are reversible at
least to some extent. Thus, CP-31398, a styrylquinazoline, can
rescue some mutant p53 to a wild-type conformation and
therefore increase the steady-state wild-type p53 to high levels
equivalent to those observed following DNA damage [25,26].
Nutlins are imidazoline derivatives that specifically bind and
dissociate MDM2 from p53, thereby rescuing p53 from
degradation [27]. Thus, such molecules have been reported to
efficiently re-activate p53, resulting in cell-cycle arrest and
apoptosis [28,29].
In the present study, we demonstrate that TNF-a induces cell
death not only in tumour vasculature but also in sarcoma tumour
cells harboring wild type p53, and that resistance to TNF-a could
be linked to lack of p53 function in this type of tumour.
Furthermore, we demonstrate that combining TNF-a with drugs
that restore the p53 pathway enhances global apoptotic effects.
These findings suggest that this combination therapy approach
could be used to treat highly resistant sarcoma tumours.
Methods
Ethics Statement
The Institutional Review Board of the Gustave Roussy Institute
(Commission Scientifique des Essais The ´rapeutiques) specifically
approved the study and all patients included in the study signed an
informed consent.
Antibodies and Reagents
Mouse anti-CD31 monoclonal antibody conjugated with Alexa
Fluor 488 was purchased from BD Pharmingen; mouse anti-p53
(DO-1) and anti-TNFR1 antibodies from Santa Cruz Biotechnol-
ogy (Santa Cruz, Ca, USA); anti-p21 and anti-MDM2 from
Calbiochem (Darmstadt, Germany); rabbit anti-BAX polyclonal
antibodies from Cell Signaling Technology (Danvers, MA, USA);
mouse anti-GAPDH monoclonal antibody from Millipore (Bill-
erica, MA, USA) and mouse anti-actin monoclonal antibody from
Sigma-Aldrich (St Louis, MO, USA). Human recombinant TNF-a
(Beromun) was obtained from Boehringer Ingelheim (Ingelheim
am Rhein, Germany). Nutlin-3a was kindly provided by Dr L.
Vassilev (Hoffman La Roche, Nutley, USA) and CP-31398 by Dr
L. Kopelovich (NIH/NCI, Bethesda, USA). TO-PRO3 was
purchased from Invitrogen (Carlsbad, CA, USA).
In Situ Cell Death Detection in Fresh STS Human Tumours
Pieces of fresh sarcoma tumours were obtained after the surgical
treatment of eight patients with resectable STS of the retroper-
itoneum. Tumours were immediately embedded in 6% low-
melting point agarose (Sigma, St. Louis, MO, USA). 200 mm thick
slices were cut at room temperature with Leica VT 1000 S
Microtome (Leica Microsystems, Wetzlar, Germany). The slices
were incubated in culture medium (RPMI containing 10% FCS)
with or without 50 ng/ml of TNF-a for 90 min at 37uC and 5%
CO2, then washed and maintained in the same conditions for 72 h
in fresh culture medium without TNF-a. Successively, cultured
slices were washed in PBS and fixed by immersion in cold
methanol for 10 min at 220uC. TUNEL reaction was performed
using in situ Cell Death Detection Kit (Roche, Foster City, CA,
USA) according to manufacturer’s instructions. Next, the slices
were incubated overnight at 4uC with mouse anti-CD31 antibody
conjugated with Alexa Fluor 488 and subsequently for 1 h with
TO-PRO3. Slices were finally mounted on glass slides using
fluoromount-G (SouthernBiotech, Birmingham, UK). Stacks of
confocal slices were collected with a LSM 510 laser scanning
confocal microscope (Carl Zeiss, Jena, Germany) using 20X/0.75
Plan-Apochromat objective. The excitation wavelengths were
488 nm for Alexa 488, 543 nm for the TUNEL positive nuclei
revealed by the Cell Death Detection Kit, and 633 nm for TO-
PRO3. Images were acquired using BP505–530, BP560–615 and
LP 650 emission filters respectively. Z-projection of stacks was
done using LSM Image Examiner software (Zeiss, Le Pecq,
France). Cell counting was done by ImageJ software using the cell
counter plugin and the percentage of apoptotic endothelial and
tumour cells was determined.
Cell Lines
Rhabdomyosarcoma cell line (KYM-1) [30] was kindly provid-
ed by Dr. T. Meager (National Institute for Biological Standards
and Control, United Kingdom), fibrosarcoma cell line (HT1080)
[31] by Dr. L. Maggiorella (IGR, Villejuf, France). Liposarcoma
cell lines (T449, T778 and T1000) [32,33] were provided by Dr. F.
Pedeutour (Nice University, Nice, France) malignant fibrous
histiocytoma (MFH152, MFH100, MFH95) [34] and leiomyosar-
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(Institut Curie, Paris, France).
Cell Culture and Treatments
HT1080 cells were grown in DMEM (4.5 g/ml glucose) with
10% FCS, and the remaining cell lines in RPMI supplemented
with 10% FBS and 1% sodium pyruvate (Gibco, Villebon sur
Yvette, France). To study TNF-a effects, cells were seeded at 25%
confluency, and one day later they were either treated with 50 ng/
ml TNF-a alone or in combination with 7.5 mg/ml CP-31398 or
5 mM Nutlin-3a for the indicated times. For cell irradiation, we
administered 15 Gy using the MXR2225/22 X-ray machine
(Comet AG, Flamett, Switzerland) at a dose rate of 1 Gy/min.
TP53 Sequencing
DNA from cell lines was extracted from cell pellets with
QIAamp Blood Tissue Kit (Qiagen, Hilden, Germany) according
to manufacturer’s instructions. Resequencing of TP53 gene was
performed by Sanger sequencing based on PCR product and did
not include generation of new data as the reference sequence used
for primer design and for alignment was already published and
available in RefSeq database as NM_000546.4 for TP53 (tumor
protein p53; Other Aliases: FLJ92943, LFS1, TRP53, p53). PCR
amplification of 9 amplicons covering exons 2 to 11 (correspond-
ing to the whole coding sequence), including at least 20 bases in
flanking introns was performed. Detailed protocol and primer
sequences are available on demand. Purified DNA was sequenced
using BigDyeH Terminator Cycle Sequencing Kit (Applied
Biosystems, Foster City, CA, USA). Sequencing reactions were
analyzed on 48-capillary 3730 DNA AnalyzerH in both sense and
antisense directions. All mutations detected were controlled with
independent amplification at least one time. Sequence reading and
alignment were performed with SeqScapeH software (Applied
Biosystems, Foster City, CA, USA).
Apoptosis Detection
Cell death was assessed by 3.3-dihexyloxacarbocyanine iodide
(DiOC6) and propidium iodide labeling (Molecular Probes,
Carlsbad, CA, USA) after 72 h treatment with TNF-a alone or
in combination with CP-31398 or Nutlin-3a. The samples were
analyzed on a FACSCalibur flow cytometer and data were
processed using CellQuest software (Becton Dickinson, Franklin
Lakes, NJ USA).
Western Blot Analysis
Western blot analyses were performed using specific monoclo-
nal or polyclonal antibodies according to standard protocols.
Briefly, washed cells were lysed in an adherent state in a lysis
buffer containing 3.75% SDS, 15% glycerol, 0.3 M Tris-HCl
(pH6.8), and a protease inhibitor mixture (Complete Protease
Inhibitor Mixture, Roche Molecular Biochemicals, Foster City,
CA, USA). Equivalent protein extracts (30 or 50 mg) were resolved
by SDS–PAGE, transferred to a nitrocellulose membrane (Milli-
pore, Billerica, MA, USA), and incubated overnight with
appropriate primary antibodies at 4uC. The labeling was
visualized using horseradish peroxidase-conjugated secondary
antibodies and by enhanced chemiluminescence (ECL Western
blotting Kit, Amersham Biosciences, Ve ´lizy, France).
Flow Cytometry
Cells were harvested using EDTA 1 mM, washed twice with
PBS, and incubated with anti-TNFR1 or isotype control
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
for 30 min. at 4uC, followed by incubation with phycoerythrin-
conjugated goat anti-mouse antibody (Beckman Coulter, Ville-
pinte, France). The samples were analyzed on a FACSCalibur
flow cytometer and data were processed using CellQuest software
(Becton Dickinson, Franklin Lakes, NJ, USA).
Transfections
HT1080 transfection was performed using Lipofectamine2000
Transfection Reagent (Invitrogen, Villebon sur Yvette, France),
according to the manufacturer’s instructions. Expression vectors
encoding shRNA designed for specific silencing of p53 or
luciferase were purchased from InvivoGen. Stably transfected
HT1080clones were selected with 500 mg/ml Zeocin (InvivoGen,
Toulouse, France). MFH95 cells, MFH100, and MFH152 cells
were transfected by electroporation in an Easyject electroporation
system (Equibio, 260 V, 450 mF) using the p53 encoding plasmid
pC53-SN3 for MFH-95.
Cell Cycle Analysis
Harvested cells were gently fixed in 70% cold-ethanol, and
incubated over night at 220uC. 70% ethanol was then removed
by centrifugation, and after PBS-washing, pelleted cells were
incubated at 37uC for 1 hour in a mixture containing 0.5 ml
PBX1x, 10 ml of 10 mg/ml RNAse A, and 25 ml of 1 mg/ml
propidium iodide solution. Cell cycle analysis was then performed
by flow cytometry.
Electrophoretic Mobility Shift Assay (EMSA)
For analysis of NF-kB DNA binding activity, 15 mg of nuclear
extracts were incubated with the radioactive labelled HIV-LTR
tandem kB oligonucleotide as kB probe [36]. The samples were
separated on a non-denaturating PAGE gel and signals were
detected by autoradiography.
Real-time Quantitative PCR Analysis
For apoptotic gene expression analysis, total RNA was extracted
after 16 h of treatment using Trizol (Sigma-Aldrich, St. Louis,
MO, USA) following manufacturer’s instructions, and reverse
transcription was performed using a High Capacity cDNA
Reverse Transcription Kit (Ambion, Foster City, CA, USA). For
quantification of apoptosis related genes, real time PCR (RT-
PCR) was performed using Platinum SYBR green qPCR Super-
Mix-UDG w/ROX (Invitrogen, Villebon sur Yvette, France) and
the 7900 HT Fast Real-time PCR System (Applied Biosystems,
Foster City, CA, USA). Apoptosis dedicated arrays were
elaborated by the PETC platform of INSERM U576 and
INSERM U876. The relative expression level of 91 apoptosis-
related genes was normalized using four different house-keeping
genes (GADPH, b-actin, HPRt and PPIA). For each sample, cycle
threshold (Ct) values for the housekeeping genes were determined
for normalization purposes, and delta Ct (DCt) between the mean
of target-gene values and housekeeping-genes values was calculat-
ed. Relative expression levels of target gene mRNAs between
control cells and Nutlin-3a or Nutlin-3a + TNF-a-treated cells
were calculated and expressed as fold change over control. Values
represent the mean of duplicates and are representative of two
independent experiments.
Statistical Analysis
Results are expressed as mean 6 standard deviation (SD) of
values obtained in at least three independent experiments.
Differences between samples were analysed using the 1- way
ANOVA. When it was statistically significant, post-hoc analysis
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considered statistically significant for p value inferior to 0.05/
number of comparisons. All calculations were performed using the
Microsoft Office Excel statistical analysis software 2003.
Results
TNF-a Induces Apoptosis of Sarcoma Tumour Cells
During Ex Vivo ILP
Although it is postulated that TNF-a works via its selective
antivascular mechanisms, its contribution to the antitumour
effect of ILP is still to be elucidated. In order to determine the
antitumour effects of TNF-a,a nex vivo tumour culture assay,
recapitulating conditions that might occur in vivo during ILP, was
performed. Slices from eight retroperitoneal sarcomas prepared
immediately after surgery (well differentiated liposarcoma, n=4;
undifferentiated sarcoma, n=2; and leiomyosarcoma, n=2) were
treated with or without TNF-a for 90 min, washed and then
maintained in fresh medium without TNF-a for 72 h before
TUNEL assay and subsequent labelling with anti-CD31 antibody
and TO-PRO3. Double staining of endothelial cells with anti-
CD31 antibody (green) and TUNEL (red) showed co-localization
of both colours (yellow), indicating that TNF-a induces apoptosis
of endothelial cells. Moreover, co-localization of nuclear staining
(TO-PRO3, blue) and TUNEL (red), resulting in purple, also
indicates that TNF-a induces apoptosis of tumour cells.
Untreated slices showed no or few TUNEL-positive nuclei,
excluding the possibility that spontaneous apoptosis was induced
by our experimental conditions (Fig. 1A). Further quantification
of the TUNEL-positive cells also revealed that TNF-a induces
apoptosis of endothelial cells in most patients (69.669%) whereas
for tumour cells, patients could be subdivided into three groups:
patients with low apoptosis rate (10% to 17%, n=2), patients
with moderate apoptosis rate (57 to 66%, n=3), and patients
with high apoptosis rate (85% to 95%, n=3), suggesting that
sarcoma tumour cells are differentially sensitive to TNF-a-
induced apoptosis (Fig. 1B).
Mutation Status of TP53 and Impact on TNF-a-induced
Cell Death in Sarcoma Cell Lines
Among a selection of nine different sarcoma cell lines, the
sequencing of full-length p53 cDNAs revealed that five cell lines
(KYM-1, HT1080, T449, T778 and T1000) had wild type TP53
gene (TP53
Wt). In MFH100 and MFH152 cells, TP53 had
respectively a homozygous 524 G.A (R175H) and 503 A.C
(H168P) missense mutation (TP53
Mut). In MFH95 and LMS148
cells, a TP53 deletion was observed since no amplification of TP53
exons 2 to 11 could be obtained (TP53
Null). Moreover, Western
blot analysis showed that T449, T778 and T1000 cells over-
expressed MDM2 while MFH100, MFH152, MFH95 and
LMS148 cells displayed non-functional p53 pathway based on
the absence of p53 increase following irradiation (Fig. 2A).
As TP53 status might modulate TNF-a-induced cell death
efficiency, we analysed TNF-a-induced apoptosis on our panel of
nine soft tissue sarcoma cell lines by 3.3-dihexyloxacarbocyanine
iodide (DiOC6) and propidium iodide (PI) labeling after 72 h of
TNF-a treatment. TP53
Wt/MDM2
Wt cell lines (KYM-1 and
HT1080) displayed high levels of apoptotic cells after TNF-a
treatment (40% and 82% respectively) (Fig. 2B) whereas TP53
Null,
TP53
Mut and TP53
Wt/MDM2
Ampl cell lines were resistant to TNF-
a-induced cell death (0.7% to 17% of apoptosis). To verify if the
resistance to TNF-a was not due to a low expression level of the
TNF receptor type 1 (TNF-R1), we assessed the surface expression
of TNF-R1 by flow cytometry (Fig. 2C). Most of the cell lines
expressed high levels of TNF-R1 (51% to 97%), regardless of p53
status, showing that resistance of STS cell lines to TNF-a-induced
apoptosis was not due to the absence or low expression of TNF-
R1. Taken together, these results demonstrate a high correlation
between p53 pathway status (TP53
Wt versus TP53
Null, TP53
Mut or
TP53
Wt/MDM2
Ampl) and sensitivity to TNF-a-induced apoptosis.
Figure 1. TNF-a induces apoptosis of sarcoma cells. A, Confocal
microscopy analysis of in situ cell death experiments. Slices from fresh
tumors maintained in culture with or without TNF-a were processed for
TO-PRO3 staining (blue), Alexa Fluor 488 conjugated mouse anti-CD31
antibody (green), and TUNEL assay (red). Untreated slices are
represented on the left panel and TNF-a-treated slices on the right.
Apoptotic tumor cells appear purple (empty arrow) in the merged
images at the bottom. Apoptotic endothelial cells that have undergone
apoptosis appear yellow (solid arrow). B, Quantification of TUNEL-
positive cells. Apoptotic cells were counted among 500 cells for each
tumour in untreated as well as in TNF-a treated samples. Results are
expressed in percentage of TUNEL-positive cells. Results are expressed
as mean 6 SEM.
doi:10.1371/journal.pone.0038808.g001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e38808Figure 2. TNF-a induced cell death in nine sarcoma cell lines with different p53 status. A, Western blot analysis of p53, MDM2 and p21
expression in TP53
Wt/MDM2
Wt (KYM-1 and HT1080), TP53
Wt/MDM2
Ampl (T449, T778 and T1000), TP53
Mut (MFH100 and MFH152) and TP53
Null (MFH95
and LMS148) cell lines studied after irradiation. Lysates were prepared 2 h after exposure to 15 Gy. B, Impact of TNF-a on cell survival assessed by
DiOC6/PI method after 72 h treatment. The percentage of specific apoptosis is shown as an increase of apoptotic cells (early and late apoptosis) in
comparison to untreated cells. Results from four experiments are shown. *p,0.05 versus all cell lines. C, Cell surface expression of TNF receptor type 1
detected by flow cytometry following staining with TNFR1-specific monoclonal antibody (filled histograms) and isotype-matched control (open
histograms). Percentages of positive cells and of mean fluorescence intensity are indicated; representative results from three experiments are shown.
doi:10.1371/journal.pone.0038808.g002
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Death
In order to confirm the role of p53 in TNF-a-induced apoptosis
of STS, we first knocked down p53 in the TP53
Wt/MDM2
Wt TNF-
a sensitive HT1080 cell line by stable transfection of a vector
encoding a short hairpin RNA (shRNA) targeting p53 (shRNA-
p53) or luciferase mRNA as a control (shRNA-luc) (Fig. 3A).
Silencing of p53 resulted in the abrogation of TNF-a-induced
apoptosis (29% and 36% apoptosis respectively in non-transfected
and control cells versus 3% in shRNA-p53 cells, p,0.05) (Fig. 3B).
Moreover, the inhibition of TNF-a-induced apoptosis in shRNA-
p53 transfected cells was not due to the decrease of TNF-R1
expression (data not shown).
We also transient overexpressed p53 in TP53
Null TNF-a
resistant MFH95 cell line using pC53-SN3 expression plasmid.
We obtained an efficient p53 expression associated with a
concomitant induction of p21 (Fig. 3C). To investigate the effect
of TNF-a on these cells, we performed a cell cycle analysis to
evaluate a putative cell cycle arrest due to p21 induction and to
quantify cell death represented by sub-G1 cells. We obtained an
increase in G1-phase (from 42% to 58%) as well as a decrease in S-
phase (from 30% to 17%) when p53 was overexpressed in MFH95
cells, suggesting a G1-arrest (Fig. 3D). In the presence of TNF-a
there was no effect in control cells whereas the proportion of sub-
G1 cells drastically increased in p53-expressing MFH95 cells
(24%) compared to control cells (1.8%) and to untreated p53-
expressing cell (2.5%). These results demonstrate that p53
expression in TP53
Null MFH95 cells enhanced TNF-a-induced
cell death.
Altogether, these data further highlight the role of p53 in
regulating TNF-a-induced cell death in sarcoma cell lines.
CP-31398 Sensitizes TP53
Mut Sarcoma Cell Lines to TNF-a-
induced Cell Death
The small molecule CP-31398 was reported to stabilize the
wild-type-associated epitope (mAb1620) of the p53 DNA-
binding domain, thus conferring a wild-type conformation to
mutant p53 and rescuing p53 functions [37]. Therefore, we
asked whether sarcoma cell lines treatment with CP-31398
would enhance p53 protein expression and its transcriptional
activity. Western blot analysis showed an increase in p53
protein level in MFH100 and MFH152 TP53
Mut cell lines after
24 h CP-31398 treatment (Fig. 4A). Furthermore, CP-31398
treatment increased expression of the p53 targets p21 and BAX.
These results illustrate the efficacy of CP-31398 in restoring p53
functional activity in our p53-mutated STS cell lines. In order
to investigate whether CP-31398 can restore the sensitivity of
TP53
Mut cell lines to TNF-a-induced cell death, we incubated
MFH152 and MFH100 cells with 50 ng/ml TNF-a and/or CP-
31398 (Fig. 4B). Results show that CP-31398 alone had a slight
apoptotic effect. However, CP-31398 pre-treatment followed by
72 h TNF-a had a synergistic effect on apoptosis induction in
both TP53
Mut cell lines (28% and 43% respectively for MFH152
and MFH100). These results show that in TP53
Mut cell lines,
restoration of wild-type p53 activity can enhance susceptibility
to TNF-a induced cell death.
Nutlin-3a Sensitizes TP53
Wt/MDM2
Ampl Sarcoma Cell Lines
to TNF-a Cytotoxic Action
We then examined the effect of the MDM-2 inhibitor Nutlin-3a
on TNF-a induced cell death. Nutlin-3a is a small-molecule
antagonist of MDM2 that binds in the p53-binding pocket,
preventing p53 degradation and thus restoring its transcriptional
activity [27] and leading to cycle cell arrest and apoptosis.
TP53
Wt/MDM2
Ampl sarcoma cell lines (T449, T778 and T1000)
were incubated with Nutlin-3a for 16 h. Western blot analysis
showed an increase of p53 protein level leading to p21 expression
and an increase of BAX expression, suggesting a restoration of p53
transcriptional activity after treatment (Fig 5A). Similar results
were also obtained by quantitative RT-PCR analysis, where the
increase in p53 protein level was associated with an increase of
BAX mRNA expression (Fig. 5B). However, the observed increase
in p53 protein was not accompanied by an increase of the p53
mRNA (Fig. 5B), presumably due to post-transcriptional regula-
tion by Nutlin-3a.
We then tested the effect of Nutlin-3a treatment alone or in
combination with TNF-a on cell viability, as recent studies
suggested synergistic effects of Nutlins with other chemotherapies
[33]. 72 h treatment with Nutlin-3a induced cell death in T449
and T778 cell lines (33% and 41.5% respectively) but had only
minor effects on T1000 cells (11%) (Fig. 5C). Incubation of cells
with both TNF-a and Nutlin-3a for 72 h resulted in potentiation
of TNF-a-induced cell death in T449 and T1000 cell lines (with a
respective cell death increase to 54.7% and 32% compared to
Nutlin-3a alone) (Fig. 5C). However, this potentiation was not
observed in T778 cells displaying maximal cell death in the
presence of Nutlin-3a.
Inhibition of TNF-a-induced NF-kB Activity and
Differential Apoptotic Gene Regulation in the Presence of
Nutlin-3a
It is well established that NF-kB plays a major role in TNF-a-
mediated survival [38]. Moreover, the relationship between p53,
TNF-a and NF-kB has been analyzed in MCF-7 breast cancer
cells. In this model, TNF-a was able to induce transcription of
p21 and accumulate inactive p53, but inhibition of the NF-kB
pathway abrogated p21 transcription [39]. Therefore, we
investigated whether combination of Nutlin-3a and TNF-a in
sarcoma cells interferes with the NF-kB-activity, which might
explain the observed potentiation of TNF-a-induced cell death in
the presence of Nutlin-3a. For this purpose, we analyzed NF-kB-
DNA binding activity by Electrophoretic Mobility Shift Assay
(EMSA) in T1000, T449 and T778 cells. TNF-a treatment
induced NF-kB binding activity in T1000 and T449 compared
to that seen in untreated cells or cells treated with Nutlin-3a
alone. Importantly, NF-kB DNA binding was markedly de-
creased when Nutlin-3a and TNF-a were combined (Fig. 6A).
Remarkably, in the T778 cell line, significant constitutive binding
of NF-kB to DNA was observed, which was inhibited in the
presence of Nutlin-3a. This constitutive binding may explain the
particular sensitivity of this cell line to Nutlin-3a and thus the
absence of amplification of the effect with TNF-a. Furthermore,
in order to understand the mechanisms involved in the
attenuation of cell lines resistance to TNF-a, we analysed the
expression level of 94 genes potentially involved in the regulation
of apoptosis in T449 and T1000 versus T778 cells using real-
time PCR. No significant difference was observed in the
expression of most genes tested between these two types of cell
lines (data not shown). However in T449 and T1000 cells, TNF-
a combined with Nutlin-3a significantly increased the mRNA
levels of TP53BP2 and GADD45, which are involved in the
inhibition of cell-cycle progression and apoptosis promotion
(Fig. 6B). TNF-a combined with Nutlin-3a also significantly
decreased the mRNA levels of the anti-apoptotic genes TGF-b1
and FAIM. The mRNA levels of all these genes were unchanged
in the T778 cell line.
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TNF-a combined with melphalan has become the standard
treatment for advanced limb sarcoma with a good benefit/risk
ratio [4] and a remarkable response rate in human patients with
heavily pre-treated disease. Clinical information gained from
radiological studies and pathological biopsies showed that TNF-a
targeted the tumour vasculature and had no visible direct effects
on tumour cells [40], although direct selective cytotoxic activity
against tumour cells has been described in vitro [17] with wide
variation of tumour cell sensitivity. In the course of these studies,
we asked whether in the context of ILP, tumour cell killing could
Figure 3. Effects of p53 silencing and overexpression on TNF-a-induced cell death. A, TP53
Wt/MDM2
Wt cell lines (HT1080) were transfected
with expression vectors encoding shRNA specific for either luciferase (shRNA-luc) or p53 (shRNA–p53) and efficiency was controlled by Western-blot.
B, Apoptosis induction after 72 h TNF-a treatment in non-transfected and transfected (shRNA) HT1080 cell lines. Representative results of induced
apoptosis from two experiments are shown. *p,0.05 versus p53 expressing cells transfected and non-transfected by shRNA-Luc. C, MFH95 TP53
Null
cell lines were transfected with p53-encoding plasmid pC53-SN3 and efficiency was controlled by Western-blot. D, Cell cycle analysis of control and
p53-expressing MFH95 cell lines treated or not by TNF-a. Percent of cells in each phase of the cell cycle is indicated at the upper right corner.
doi:10.1371/journal.pone.0038808.g003
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data indicate that TNF-a was able to induce ex vivo apoptosis of
sarcoma tumour cells.
It should be noted that one of the hallmarks of STS is their
pronounced resistance to apoptosis, resulting in cell survival or
absence of cell damage even when confronted to multiple stress
stimuli [2]. Indeed, in our in situ cell death detection experiments,
two out of eight STS tumours appeared to be completely resistant
to TNF-a effects and three others displayed partial tumour
resistance. Accumulating evidence indicates that p53 dysregulation
is very common in STS and that p53 mutations correlate with
increased resistance to current therapeutic strategies [23]. Since a
relationship between TP53 status and tumour sensitivity to TNF-a
was previously reported in a human breast cancer model [18,19],
and given that drugs restoring p53 function are now available, we
investigated the impact of p53 in the context of resistance to TNF-
a in STS cell lines. We demonstrated that STS tumour resistance
to TNF-a-induced-cell death was also associated with p53
inactivation (by point mutation or MDM2 amplification). More-
over, p53 silencing in a TP53
Wt cell line inhibited sensitivity to
TNF-a-cytotoxicity, and p53 overexpression in TP53
Null cells
restored it. These data strengthen the critical role of p53 in TNF-
a-induced cell death in STS. However, a role for p53-independent
pathways such as those related to p73/63 [41] have been reported
to induce apoptosis. Since our p53-inactivated cell lines were not
consistently killed by TNF-a, these alternate pathways are not
obviously involved in the response to TNF-a in our STS cell lines.
It is well known that the conformation of the DNA-binding
domain of p53 is flexible and that conformational changes in
mutant p53 are reversible. Thus, restoration of p53 wild-type
function to the highly accumulated mutant p53 in tumour cells
may possibly result in a considerable therapeutic response [24]. In
this regard, we investigated the effect of CP-31398, a small
molecule known to rescue p53 functions. In this report, we provide
evidence that this compound was able to attenuate STS resistance
to TNF-a. An improvement of TNF-a killing efficiency can thus
be obtained when used in association with p53 re-activating agents
in the context of p53 mutation.
Moreover, the recent use of MDM2 inhibitors of the Nutlin
group has been reported to be a promising new therapeutic
strategy for human tumours retaining wild-type p53 status. Nutlin-
3a is a highly selective inhibitor of the MDM2-p53 interaction by
competitive binding. Consequently, it potently stabilizes and
activates wild-type, but not mutant p53 protein in tumour cells
in contrast to chemotherapeutics whose mechanism of action, at
least in part, relies on genotoxic activation of p53. Importantly,
there is evidence that Nutlins, while being toxic to cancer cells, do
not induce cell death or apoptosis in normal non-malignant cells
and tissues [27,42]. In our study, Nutlin-3a effectively restored the
p53 pathway in the TP53
Wt/MDM2
Ampl liposarcoma cell lines
Figure 4. Restoration of p53 function with CP-31398 sensitizes sarcoma cells to TNF-a-induced apoptosis. A, Western-blot analysis of
p53 target gene expression in TP53
Mut cell lines (MFH100 and MFH152) after 24 h treatment with CP-31398. B, Apoptosis induction after 96 h of
culture. Cells were treated either with CP-31398 alone (24 h), TNF-a alone (72 h) or both sequentially (24 h with CP followed by 72 h with TNF-a).
Apoptosis was measured after 96 h by DiOC6/PI labeling; results from three independent experiments are shown. * p,0.05 versus CP-31398 or TNF-a
treated cells.
doi:10.1371/journal.pone.0038808.g004
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a could reverse the observed resistance of TP53
Wt/MDM2
Ampl
sarcoma cell lines to TNF-a.
It has been reported that in p53-mutated cell lines, NF-kB was
induced at higher levels following TNF-a treatment [43] and that
TNF-a-induced apoptosis in these cells was modulated by
mutated p53 as well as by the NF-kB induction [44]. Moreover,
it is well known that NF-kB has a protective action against TNF-
a-induced cell death, suggesting that NF-kB inhibition may
potentiate TNF-a-induced apoptosis [45]. In this regard, Nutlin-
3a was shown to suppress TNF-a-induced NF-kB reporter
activation, and to inhibit transactivation of NF-kB target genes
[46]. Here we show that TNF-a-induced NF-kB-DNA binding is
differentially modulated in TP53
Wt/MDM2
Ampl sarcoma cell lines,
demonstrating a sensitization effect with the combined treatment
of TNF-a and Nutlin-3a. In addition, our data highlight that
some pro-(TP53BP2 and GADD45) and anti-apoptotic genes
(TGF-b1 and FAIM) display a different pattern of transcript
induction and repression in sensitized cell lines when the
combination of Nutlin-3a and TNF-a is used. Further studies
are thus needed to determine the molecular mechanisms
associated with the potentiating pro-apoptotic effect of TNF-a
combined with Nutlin-3a, and to determine whether NF-kB-
DNA binding repression by Nutlin-3a is involved in the observed
potentiation of apoptosis when both TNF-a and Nutlin-3a are
used. Indeed, this may have important implications since the use
of both CP-31398 and Nutlin-3a, which act on various pathways,
Figure 5. Restoration of p53 pathways by Nutlin-3a in TP53Wt/MDM2Ampl cells. A, Induction of p53 target genes in TP53Wt/MDM2Ampl
(T449, T778 and T1000) cell lines after 16 h treatment with Nutlin-3a detected by Western blotting. B, Expression of p53 and BAX transcripts after 16 h
treatment with Nutlin-3a detected by RT-PCR. The results are shown as fold induction relative to cells treated with medium. * p,0.05 versus
untreated cells. C, Apoptosis induction after Nutlin-3a or/and TNF-a treatment for 72 h in TP53Wt/MDM2Ampl cell lines. Apoptosis was detected by
DiOC6/PI assay. Results from three independent experiments are shown. * p,0.05 versus T449 or T1000 with TNF-a or Nutlin-3a treatment. p,0.05
versus T1000 with Nutlin-3a treatment. ** p,0.05 versus T778 with TNF-a treatment.
doi:10.1371/journal.pone.0038808.g005
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PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e38808Figure 6. Differential NF-kB-DNA-binding and apoptotic gene expression are involved in the potentiating effect of TNF-a and
Nutlin-3a treatment. A, NF-kB DNA binding activity after treatment of the TP53Wt/MDM2Ampl cell lines with TNF-a or/and Nutlin-3a. Nuclear
extracts from monolayers of T449, T778 and T1000 cells, untreated or treated with either TNF-a, or Nutlin-3a or both for 72 h, were analyzed for NF-kB
activity by EMSA. B, Differentially regulated apoptotic genes in TP53Wt/MDM2Ampl cell lines treated with the combination of TNF-a and Nutlin-3a
compared to Nutlin-3a-only treated cells. T449, T778 and T1000 cell lines were treated 16 h with 50 ng/ml TNF-a and/or 5 mmol Nutlin-3a. Total RNA
was extracted and analyzed by qRT-PCR. Results are expressed as mean 6 SD from two independent experiments performed in duplicate. * p,0.05 in
TNF-a + Nutlin-3a treated cells as compared to Nutlin-3a alone.
doi:10.1371/journal.pone.0038808.g006
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result in a more efficient therapeutic response.
In conclusion, our data indicate that activating p53 with CP-
31398 or Nutlin-3a, in respectively TP53
Mut and TP53
Wt/
MDM2
Ampl cell lines, restores sensitivity to TNF-a. This is of
importance in the clinical setting where the use of TNF-a
administered locally and in combination with other drugs that
restore the p53 pathway may contribute to improved efficacy of
such therapy. These findings thus provide a new strategy for
treating highly refractory STS, in which p53 is frequently mutated
or inactivated.
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